Homepage - Cardiol Therapeutics

A clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease

COVID-19 and CVD

Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).

Learn More

Acute Myocarditis

Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.

Learn More